Bibliography
- Fielding CJ, Fielding PE. Reverse cholesterol transport – new role for pre-β1-HDL and lecithin:cholesterol acyltransferase. In: High Density Lipoproteins. Fielding CJ, editor. Wiley-VCH, Verlag; 2007. p. 143-61
- Segrest JP, Garber DW, Brouillette CG, et al. The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 1994;45:303-69
- Yokoyama S. Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol 2006;26(1):20-7
- Cavelier C, Lorenzi I, Rohrer L, et al. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta 2006;1761(7):655-66
- Krimbou L, Marcil M, Genest J. New insights into the biogenesis of human high-density lipoproteins. Curr Opin Lipidol 2006;17(3):258-67
- Davidson WS, Thompson TB. The structure of apolipoprotein A-I in high density lipoproteins. J Biol Chem 2007;282(31):22249-53
- Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006;31(8):445-54
- Wong K, Ryan RO. Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation. Curr Opin Lipidol 2007;18(3):319-24
- Dudley-Brown S. A shot of good cholesterol: synthetic HDL, a new intervention for atherosclerosis. J Cardiovasc Nurs 2004;19(6):421-4
- Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290(17):2292-300
- Calabresi L, Sirtori CR, Paoletti R, et al. Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 2006;8(2):163-7
- Marchesi M, Sirtori CR. Therapeutic use of the high-density lipoprotein protein and peptides. Expert Opin Investig Drugs 2006;15(3):227-41
- Nath A, Atkins WM, Sligar SG. Applications of phospholipid bilayer nanodiscs in the study of membranes and membrane proteins. Biochemistry 2007;46(8):2059-69
- Rensen PC, De Vrueh RL, Kuiper J, et al. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001;47:251-76
- Lacko AG, Nair M, Paranjape S, et al. Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy 2006;52:171-3
- Jonas A. Reconstitution of high-density lipoproteins. Methods Enzymol 1986;128:553-82
- Yamamoto T, Ryan RO. Anionic phospholipids inhibit apolipoprotein E – low-density lipoprotein receptor interactions. Biochem Biophys Res Commun 2007;354:820-4
- Lapinski MM, Castro-Forero A, Greiner AJ, et al. Comparison of liposomes formed by sonication and extrusion: rotational and translational diffusion of an embedded chromophore. Langmuir 2007;23(23):11677-83
- Oda MN, Ryan RO. Apolipoprotein A-I structure. In: High Density Lipoproteins Fielding CJ, editor. Wiley-VCH, Verlag; 2007. p. 3-23
- Peters-Libeu CA, Newhouse Y, Hall SC, et al. Apolipoprotein E*dipalmitoylphosphatidylcholine particles are ellipsoidal in solution. J Lipid Res 2007;48(5):1035-44
- Tubb MR, Silva RA, Pearson KJ, et al. Modulation of apolipoprotein A-IV lipid binding by an interaction between the N and C termini. J Biol Chem 2007;282(39):28385-94
- Beckstead JA, Wong K, Gupta V, et al. The C terminus of apolipoprotein A-V modulates lipid-binding activity. J Biol Chem 2007;282(21):15484-9
- Chromy BA, Arroyo E, Blanchette CD, et al. Different apolipoproteins impact nanolipoprotein particle formation. J Am Chem Soc 2007;129(46):14348-54
- Beckstead JA, Block BL, Bielicki JK, et al. Combined N- and C-terminal truncation of human apolipoprotein A-I yields a folded, functional central domain. Biochemistry 2005;44(11):4591-9
- Tufteland M, Pesavento JB, Bermingham RL, et al. Peptide stabilized amphotericin B nanodisks. Peptides 2007;28(4):741-6
- Nichols AV, Gong EL, Blanche PJ, et al. Characterization of discoidal complexes of phosphatidylcholine, apolipoprotein A-I and cholesterol by gradient gel electrophoresis. Biochim Biophys Acta 1983;750:353-64
- Nguyen TS, Weers PM, Raussens V, et al. Amphotericin B induces interdigitation of apolipoprotein stabilized nanodisk bilayers. Biochim Biophys Acta 2008;1778(1):303-12
- Hamilton-Miller JM. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev 1973;37(2):166-96
- Hartsel S, Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol Sci 1996;17(12):445-9
- Lemke A, Kiderlen AF, Kayser O. Amphotericin B. Appl Microbiol Biotechnol 2005;68(2):151-62
- Herbrecht R, Natarajan-Ame S, Nivoix Y, et al. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003;4(8):1277-87
- Oda MN, Hargreaves P, Beckstead JA, et al. Reconstituted high-density lipoprotein enriched with the polyene antibiotic, amphotericin B. J Lipid Res 2006;47:260-7
- Hargreaves, PL, Nguyen TS, Ryan RO. Spectroscopic studies of amphotericin B solubilized in nanoscale bilayer membranes. Biochim Biophys Acta 2006;1758:38-44
- Slater JL, Huang CH. Interdigitated bilayer membranes. Prog Lipid Res 1988;27:325-59
- Tufteland M, Ren G, Ryan RO. Apolipoprotein induced transformation of amphotericin B lipid complex into nanodisks. J Pharm Sci In Press; 2008 Feb 12 [Epub ahead of print]
- Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 2007;14:1153-69
- Nelson KG, Bishop J, Ryan RO, et al. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2006;50:1238-44
- Umesono K, Gigeure V, Glass, CK, et al. Retinoic acid and thyroid hormone induce gene expression through a common responsive element. Nature 1988;336:262-5
- Gianni M, Ponzanelli I, Mologni L, et al. Retinoid-dependent growth inhibition, differentiation, and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ 2000;7:447-60
- Duprez E, Wagner K, Koch H, et al. C/EBPβ: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J 2003;22:5806-16
- Sun S, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41-55
- Freedman LP. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 1999;97:5-8
- Redmond KA, Nguyen TS, Ryan RO. All-trans retinoic acid nanodisks. Int J Pharm 2007;339:246-50
- Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22:7305-15
- Arce F, Gätjens-Boniche O, Vargas E, et al. Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2. Cancer Lett 2005;229:271-81
- Benbrook D, Lernhardt E, Pfahl M. A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature 1988;333:669-72
- Kodama T, Freeman M, Rohrer L, et al. Type I macrophage scavenger receptor contains a-helical and coiled-like coils. Nature 1990;343:531-5
- Rohrer L, Freeman M, Kodama T, et al. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature 1990;343:570-2
- Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? – a mouse's tale. J Clin Invest 2001;108:649-54
- Pearson AM, Rich A, Krieger M. Polynucleotide binding to macrophage scavenger receptors depends on the formation of base-quartet-stabilized four stranded helices. J Biol Chem 1983;268:3546-54
- Haberland ME, Olch CL, Fogelman AM. Role of lysines in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages. J Biol Chem 1984;259:11305-11
- Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983;52:223-61
- Zhang H, Yang Y, Steinbrecher UP. Structural requirements for the binding of modified proteins to the scavenger receptor of macrophages. J Biol Chem 1993;268:5535-42
- Brown MS, Basu SK, Falck JR, et al. The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J Supramol Struct 1980;13:67-81
- Ryan RO, Oikawa K, Kay CM. Conformational, thermodynamic and stability properties of insect apolipophorin III as determined by circular dichroism and fluorescence spectroscopy. J Biol Chem 1993;268:1525-30
- Weers PMM, Narayanaswami V, Kay CM, et al. Interaction of an exchangeable apolipoprotein with phospholipid vesicles and lipoprotein particles. Role of leucines 32, 34 and 95 in Locusta migratoria apolipophorin III. J Biol Chem 1999;274:21804-10
- Soulages JL, Bendavid OJ. The lipid binding activity of the exchangeable apolipoprotein apolipophorin-III correlates with the formation of a partially folded conformation. Biochemistry 1998;37:10203-10
- Weers PMM, Narayanaswami V, Ryan RO. Modulation of the lipid binding properties of the N-terminal domain of human apolipoprotein E3. Eur J Biochem 2001;268:3728-35
- Wang J, Sykes BD, Ryan RO. Structural basis for the conformational adaptability of apolipophorin III, a helix-bundle exchangeable apolipoprotein. Proc Natl Acad Sci USA 2002;99:1188-93
- Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005;23:6409-14
- Shan D, Press OW, Tsu TT, et al. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J Immunol 1999;162:6589-95
- Hamdy N, Goustin AS, Desaulniers JP, et al. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. J Immunol Methods 2005;297(1-2):109-24